Psychopharm Cmte. Crafts Statement To Avoid Public Misunderstanding
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee crafted a statement on the need for long-term efficacy data for psychiatric drugs in order to avoid public misperception of the outcome of its Oct. 25 meeting